Get to know our clinical trials
Clinical trial of IO102-IO103 in combination with pembrolizumab compared to pembrolizumab alone in patients with previously untreated unresectable or metastatic (advanced) melanoma.
THE MAIN OBJECTIVE OF THIS STUDY IS TO FIND OUT HOW WELL THE STUDY DRUG (IO102-IO103) WORKS WHEN COMBINED WITH PEMBROLIZUMAB AND TO WHAT EXTENT IT IS SAFE COMBINED WITH PEMBROLIZUMAB COMPARED TO PEMBROLIZUMAB ON A MONOTHERAPY REGIMEN (ALONE).
Status
In recruitment
headquarters
Madrid
Technical Summary
- PHASE III, OPEN-LABEL, RANDOMIZED CLINICAL TRIAL OF IO102-IO103 IN COMBINATION WITH PEMBROLIZUMAB COMPARED TO PEMBROLIZUMAB ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC (ADVANCED) MELANOMA. IMMUNOTHERAPY
- Code EudraCT: 2021-004594-32
- Protocol number: IO102-IO103-013
- Promoter: IO Biotech ApS
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.